Clin2
NCT07016126Possibly a fitRecruiting

Study of D-BACE, chemo, and carlizumab for lung cancer

NSCLC (Non-small Cell Lung Cancer)

Part of Cancer, Lungs & breathing clinical trials.

This trial tests a combination of a new drug (D-BACE), chemotherapy, and carlizumab for people with a certain type and stage of lung cancer that can be removed with surgery. It aims to see if this combination helps shrink tumors and improves outcomes.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
70 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old.
  • You have been diagnosed with stage II, IIIA, or potentially resectable stage IIIB non-small cell lung cancer (NSCLC).
  • Your cancer has not been previously treated with immunotherapy, targeted therapy, or chemotherapy.
  • You are able to provide a tumor tissue sample for testing.
  • Your doctor has confirmed your lung function and other organs can handle surgery.
  • You must use effective birth control during and for a period after treatment (if applicable to you).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07019675Recruiting· Phase 2
Study of a new drug for people with lung cancer

This trial tests a new medication, SKB518, for people with non-small cell or small cell lung cancer who have at least one measurable tumor and are in fairly good health. It aims to see if the drug can help shrink tumors or slow the cancer's growth.

Shenzhen, Guangdong
NCT05351788Recruiting· Phase 2
Study drug combo for advanced lung cancer with specific gene results

This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.

Guangzhou, Guangdong
NCT07739186Not yet recruiting· Phase 2/Phase 3
First-line treatment for advanced non-squamous lung cancer

This trial tests a new drug combination for people with a type of lung cancer that has spread or cannot be removed by surgery. It compares the new combination to the current standard treatment to see which works better.

Guangzhou, Guangdong
NCT06127329Not yet recruiting
BAI & DEB-BACE for advanced NSCLC

This trial tests a new way to treat advanced NSCLC by combining two non-surgical procedures: bronchial artery infusion (BAI) and drug-eluting bead bronchial artery chemoembolization (DEB-BACE). It may be an option if you have stage III or IV lung cancer and standard treatments have failed or are not possible.

Zhengzhou, Henan
NCT07738367Enrolling by invitation· Phase 2
Bronchial artery chemoembolization with drug therapy for advanced lung cancer

This trial tests a treatment called bronchial artery chemoembolization (BACE) combined with drug therapy for advanced non-small cell lung cancer. BACE delivers chemotherapy directly to the tumor through the blood vessel that feeds it, which may help control the cancer when standard treatments have stopped working.

Fuzhou, Fujian
NCT06377735Recruiting
BAI-BACE for advanced lung squamous cell carcinoma

This trial is testing a new use of a procedure called BAI-BACE (injecting drugs or blocking blood flow through the bronchial artery) for people with advanced lung squamous cell carcinoma that hasn't responded to prior treatments. The goal is to see if this treatment can help control the cancer when it's still only in the chest.

Beijing, Beijing Municipality

Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.